pantoprazole

This page shows the latest pantoprazole news and features for those working in and with pharma, biotech and healthcare.

Pfizer settles US Protonix lawsuit for $785m

over-charged Medicaid for Protonix (pantoprazole), failing to offer the federal government the same discounts it was offering to private customers.

Pfizer 2014 guidance threatened by Celebrex competition

The early onset of generic competition to Celebrex comes after a torrid time for Pfizer in terms of patent losses, with cholesterol lowerer Lipitor (atorvastatin), gastrointestinal medicine Protonix (pantoprazole), Viagra (sildenafil)
Teva defends Copaxone from Dutch patent challenge

Maintaining Copaxone revenues is particularly important for Teva after it was ordered to pay $1.6bn in compensation to Pfizer and Takeda for infirming the patent on their Protonix (pantoprazole) gastrointestinal
Takeda expands Latin American footprint

These will be ulcer treatments Zurcal (pantoprazole) and Riopan (Magaldrate Dimeticone), the anti-inflammatory Faktu (Policresulen, Cinchocaine hydrochloride) and Albothyl (Policresulen), a gynaecology product.
Pfizer sales dip as net income surges in Q2

from the spin-out of Zoetis and a litigation settlement with Teva and Sun Pharmaceutical Industries for patent infringement of Protonix (pantoprazole) fell 5 per cent.
Teva and Sun pay dearly for 'at-risk' generic Protonix launch

The settlement marked the end of almost a decade of litigation over the intellectual property for Protonix (pantoprazole), and is the first time that generic pharma companies have been punished for ... Teva and Sun took a risk in 2007 and 2008 when they

More from news
Approximately 1 fully matching, plus 28 partially matching documents found.

Pharma deals during June 2013

Top of the table is the patent settlement between Pfizer/ Takeda and Teva/ Sun Pharmaceutical for the launch of generic versions of Protonix (the proton pump inhibitor, pantoprazole) in 2007 ahead
Interview: Trevor Smith, Takeda

For Nycomed this meant loss of exclusivity (LOE) on its blockbuster gastroinestinal drug pantoprazole and the consequent need to reorganise its business.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Account Director, Medical Communications & Events: £50 - 65, 000 according to skills and experience benefits

Scientific Director – Medical Communications - New York or Remot...: $100000 - $150000

Integrated Brand/ Digital Senior Account Director, London: Excellent package

Principal Medical Writer / Editorial Director – Medical Communic...: £60, 000 - £80, 000

Senior Account Manager / Account Director - Medical Education – ...: Salary TBC

Senior Medical Writer, Principal Medical Writer, Scientific Dire...: £40000 - £75000 Bonus Benefits

Science Writer, Healthcare Advertising Agency: £40, 000 - 45, 000 DOE benefits,

Senior/ Market Access Consultant, UK, HOME BASED, £50-60K: Excellent package

Add my company

Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...

The gene therapy revolution: Gene therapies are bringing new hope for many people with diseases caused by genetic disorders...
PM Society Digital Awards – the power of together: Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduce anyone in four simple steps: You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...